Generic Name and Formulations:
Dinoprostone 10mg; controlled-release vaginal insert w. retrieval system.
Indications for CERVIDIL:
Cervical ripening in patients at or near term when there is an indication for labor induction.
Fetal distress where delivery is not imminent. Unexplained vaginal bleeding. Presence or suspicion of cephalopelvic disproportion. Where oxytocics or prolonged uterine contractions are inappropriate, including previous cesarean section, major uterine surgery. Multipara with ≥6 previous term pregnancies. Concomitant oxytocics. Remove insert if uterine hyperstimulation, labor, sustained uterine contractions, or other fetal/maternal adverse reactions occur and prior to amniotomy.
For hospital use when appropriate obstetric care is present. Ruptured membranes. Non-vertex, non-singleton presentation. Previous uterine hypertony. Glaucoma. History of childhood asthma. Monitor uterine activity, fetal status, cervical dilatation/effacement. Pregnancy (Cat.C).
Potentiates oxytocics; delay administration of oxytocics at least 30 minutes after removal of insert.
Uterine hyperstimulation, fetal distress.
Clinical Pain Advisor Articles
- Cannabis Use High in Migraine
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Percutaneous Electrolysis May Be Useful Adjunct for Subacromial Pain Syndrome
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use